A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS?

摘要

BackgroundPotent direct-acting antivirals (DAAs) for treatment of chronic hepatitis C virus (HCV) infection have reduced the need for on-treatment monitoring. Currently, on-treatment response and outcome are determined by HCV RNA testing. A less expensive alternative to verify viral replication is HCV core antigen (HCV Ag).